Evidence map›Paper›PMID 41341327›Full record

ArticleCureus2025

Alport Syndrome: A Case of Delayed Diagnosis Through Genetic Testing.

Farid Arman, Niloofar Nobakht, Dianne S Cheung, Huma Kennedy

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Farid ArmanDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, USA.
Niloofar NobakhtDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, USA.
Dianne S CheungDepartment of Medicine/Endocrinology, Diabetes, and Metabolism, David Geffen School of Medicine at UCLA, Los Angeles, USA.
Huma KennedyDepartment of Medicine, Division of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alport syndrome (AS) is a genetic disorder characterized by progressive kidney dysfunction, hearing loss, and ocular abnormalities, with microscopic hematuria often being the initial presenting symptom. Despite being well-recognized among nephrologists, AS has historically been underdiagnosed or misdiagnosed, primarily due to restricted access to genetic testing and its underutilization in clinical practice. The advent of commercial genetic testing has improved diagnostic accuracy. This case report describes a patient with longstanding AS diagnosed late in life through genetic testing.

Indexed as

alport’s syndromeasymptomatic hematuriabilateral hearing lossgenetic testnephrotic-range proteinuria

Identifiers

PMID41341327
PMCPMC12670061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.